Biotech Values

[Titan V]

Just to add, all patients in the upcoming p2 registration trial, and the 20 that will be added to the current p2b trial at UCSF, will be actual non-responders from previous anti-PD-1 monotherapy (mostly Keytruda). I cannot imagine MRK not being interested in acquiring ONCS (or their lead program) if they are able to produce 30%+ CRs in a larger non-responder population, esp. given this combination could be expanded to other solid tumors too.